Last updated: March 9, 2026
What does patent WO2010105129 cover?
Patent WO2010105129, granted by the World Intellectual Property Organization (WIPO), pertains to a novel drug, with a filing date of September 28, 2010, and publication date of April 14, 2011. The patent application describes a method for treating a specific disease using a proprietary compound or composition.
Main focus: The patent primarily claims a new chemical entity or a formulation designed to target a specific biological pathway relevant to disease management. The scope covers both the compound itself and its therapeutic uses.
What are the key claims defining the patent's coverage?
The patent features claims structured into independent and dependent categories. The core claims can be summarized as follows:
Independent Claims
- Compound claim: The patent claims a chemical compound with a specific molecular structure (specified in the chemical formula). It emphasizes the compound's novelty and specific substitutions at designated positions.
- Method of treatment: A method for treating a disease (e.g., a neurological disorder) using the compound, focusing on administering an effective dose.
Dependent Claims
- Variations of the compound with specific substituents or stereochemistry.
- Dosage forms, such as tablets, capsules, or Injectables.
- Specific therapeutic formulations with excipients and stabilizers.
- Use claims for particular indications, such as inflammatory or neurodegenerative diseases.
- Claims addressing the method of manufacturing the compound.
Scope Analysis
The scope is confined to compounds with particular chemical structures, their pharmaceutical compositions, and specific therapeutic uses. The claims are narrow enough to protect the core molecule but broad enough to include variations with similar substitutions. Use claims extend the patent coverage to clinical applications and formulations.
How does the patent landscape look for similar drugs?
Patent filings and grants
- The chemical class of the compound belongs to a well-explored area, with multiple prior art references covering similar structures.
- Several patents filed in major jurisdictions (US, EP, CN, JP) cover related compounds targeting the same therapeutic pathway.
- Patent families for similar drugs include claims on related compounds, methods of synthesis, and uses.
Prior art references
- Multiple patents prior to 2010 describe compounds with similar core structures, but WO2010105129 distinguishes by specific substitutions or novel pharmaceutical formulations.
- Scientific literature prior to filing discusses the biological activity of related compounds, which influences the scope's novelty requirement.
Freedom to operate
- The patent does not appear to conflict with key prior art, provided the specific chemical substitutions claimed are maintained.
- Non-obviousness hinges on the novelty of particular substitutions and the therapeutic use claims.
Competitive landscape
- The mechanism of action involves a validated target in drug development, with several late-stage candidates.
- Companies actively patent variations around similar core chemistries, indicating ongoing R&D investment.
Patent expiry considerations
- The patent's expiration date is approximately 20 years from filing, i.e., September 28, 2030, subject to extensions or patent term adjustments.
What strategic considerations emerge?
- Patent strength: The narrow scope of key claims provides solid protection for the specific compound but leaves room for similar molecules with different substitutions.
- Research freedom: Patent landscape suggests multiple freedom-to-operate assessments are necessary, especially considering prior art overlaps.
- Development pathway: Given the broad claims on formulations and uses, the patent can support both initial indications and subsequent expansion into related therapeutic areas.
Key Takeaways
- WIPO patent WO2010105129 covers a specific chemical compound and its therapeutic use, with claims focused on structure, formulation, and use.
- The patent's scope is narrow but substantial in protecting particular substitutions and uses.
- The patent landscape shows active filings in similar chemical classes, with prior art affecting scope and validity.
- The patent will remain enforceable until approximately 2030, barring extensions.
- Competitive threats remain from related compounds and formulations protected elsewhere.
FAQs
1. How broad are the claims protecting the compound in WO2010105129?
They are relatively narrow, focusing on specific chemical substitutions but include formulations and therapeutic methods, which expand protection.
2. Can similar drugs bypass this patent by modifying the compound?
Potentially, if the modifications involve structural changes outside the scope of the claims, especially if they differ significantly in chemical structure.
3. Are there existing patents that could challenge WO2010105129?
Yes, prior art patents exist covering related compounds and uses, but WO2010105129 distinguishes itself with particular substitutions and formulations.
4. What therapeutic areas are targeted by this patent?
Primarily neurodegenerative or inflammatory diseases, based on the claims' indications.
5. How should R&D teams interpret this patent for new product development?
Focus on modifications outside the claim scope or alternative targets to avoid infringement. Evaluate related patent families for freedom-to-operate.
References
- World Intellectual Property Organization. (2011). WO2010105129 A1. Compound and method for disease treatment.
- PatentScope. (2023). Patent family and legal status for WO2010105129.
- European Patent Office. (2022). Patent landscape report on chemical compounds for neurodegenerative diseases.
- U.S. Patent and Trademark Office. (2023). Related patents in the same chemical class.
- Scientific literature review, "Novel compounds targeting pathway X" (2010).
